RXST
RxSight, Inc.NASDAQHealthcare$6.64+5.72%ClosedMarket Cap: $274.0M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.05
P/S
2.15
EV/EBITDA
-7.08
DCF Value
$-251.96
FCF Yield
0.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
76.6%
Operating Margin
-35.8%
Net Margin
-29.0%
ROE
-14.0%
ROA
-12.5%
ROIC
-16.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $32.6M | 77.5% | $-11.3M | $-9.2M | $-0.22 | — |
| FY 2025 | $134.5M | 76.6% | $-48.2M | $-38.9M | $-0.95 | — |
| Q3 2025 | $30.3M | 79.9% | $-12.2M | $-9.8M | $-0.24 | — |
| Q2 2025 | $33.6M | 74.9% | $-14.0M | $-11.8M | $-0.29 | — |
| Q1 2025 | $37.9M | 74.8% | $-10.7M | $-8.2M | $-0.20 | — |
| Q4 2024 | $40.2M | 71.6% | $-8.6M | $-5.9M | $-0.15 | — |
| FY 2024 | $139.9M | 70.7% | $-36.9M | $-27.5M | $-0.71 | — |
| Q3 2024 | $45.4M | 55.5% | $-9.2M | $-6.3M | $-0.16 | — |
| Q2 2024 | $34.9M | 69.5% | $-8.3M | $-6.1M | $-0.16 | — |
| Q1 2024 | $29.5M | 70.1% | $-10.7M | $-9.1M | $-0.25 | — |
| Q4 2023 | $28.6M | 61.8% | $-10.9M | $-9.2M | $-0.26 | — |
| FY 2023 | $89.1M | 60.4% | $-50.1M | $-48.6M | $-1.41 | — |